{"id":"NCT04206020","sponsor":"Mitotech, SA","briefTitle":"Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome","officialTitle":"A Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study of Safety and Efficacy of SkQ1 Ophthalmic Solution in the Environment and the Controlled Adverse Environmental (CAEÂ®) Model for the Treatment of Dry Eye Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-12-20","primaryCompletion":"2020-10-06","completion":"2020-10-06","firstPosted":"2019-12-20","resultsPosted":"2022-01-19","lastUpdate":"2022-01-19"},"enrollment":610,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Syndrome"],"interventions":[{"type":"DRUG","name":"SkQ1 Vehicle Solution","otherNames":["Vehicle for SkQ1"]},{"type":"DRUG","name":"SkQ1 Ophthalmic Solution","otherNames":["Visomitin"]}],"arms":[{"label":"Placebo Comparator: SkQ1 Vehicle","type":"PLACEBO_COMPARATOR"},{"label":"SkQ1","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate whether SkQ1 Ophthalmic Solution is safe and effective compared to Vehicle for the treatment of the signs and symptoms of dry eye syndrome.","primaryOutcome":{"measure":"Ocular Discomfort Scale","timeFrame":"From baseline to Day 57","effectByArm":[{"arm":"Placebo Comparator: SkQ1 Vehicle","deltaMin":-0.6,"sd":1.36},{"arm":"SkQ1 Ophthalmic Solution","deltaMin":-0.6,"sd":1.34}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":10},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":306},"commonTop":["Instillation site pain","Visual acuity reduced"]}}